Aprea Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Aprea Therapeutics, Inc. (APRE) reported Increase (Decrease) in Deferred Revenue of -$528.97 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-03-16
- Aprea Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2024-12-31 was $0.00.
- Aprea Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2024-09-30 was -$50.74K.
- Aprea Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2024-06-30 was -$97.67K.
- Aprea Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2024-03-31 was -$380.57K.
- Aprea Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$528.97K, a 200.00% decline from fiscal 2023.
- Aprea Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was $528.97K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$50.74K derived: sum of 2 quarters · filed 2026-03-16 | -$148.41K derived: sum of 3 quarters · filed 2026-03-16 | -$528.97K 10-K · filed 2026-03-16 |
| 2024-09-30 | -$50.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$148.41K derived: sum of 2 quarters · filed 2025-11-12 | -$528.97K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$97.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$478.24K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$380.57K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $528.97K 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |